Supplementary Table 1 from A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Abstract

PDF file, 52KB, Adverse events that led to permanent treatment discontinuation.